PT3455257T - Anticorpos anti-pd-l1 - Google Patents
Anticorpos anti-pd-l1Info
- Publication number
- PT3455257T PT3455257T PT177242633T PT17724263T PT3455257T PT 3455257 T PT3455257 T PT 3455257T PT 177242633 T PT177242633 T PT 177242633T PT 17724263 T PT17724263 T PT 17724263T PT 3455257 T PT3455257 T PT 3455257T
- Authority
- PT
- Portugal
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662333643P | 2016-05-09 | 2016-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3455257T true PT3455257T (pt) | 2021-12-06 |
Family
ID=58710168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT177242633T PT3455257T (pt) | 2016-05-09 | 2017-05-09 | Anticorpos anti-pd-l1 |
Country Status (15)
Country | Link |
---|---|
US (3) | US10954302B2 (pt) |
EP (1) | EP3455257B1 (pt) |
JP (1) | JP6979971B2 (pt) |
KR (1) | KR102343742B1 (pt) |
CN (1) | CN109311985B (pt) |
AU (1) | AU2017264683B2 (pt) |
CA (1) | CA3021669A1 (pt) |
DK (1) | DK3455257T3 (pt) |
ES (1) | ES2899361T3 (pt) |
HU (1) | HUE055972T2 (pt) |
IL (1) | IL262295B2 (pt) |
PL (1) | PL3455257T3 (pt) |
PT (1) | PT3455257T (pt) |
SG (1) | SG11201809336QA (pt) |
WO (1) | WO2017196867A1 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014332458B2 (en) | 2013-09-05 | 2020-03-12 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies |
US10822399B2 (en) | 2014-02-10 | 2020-11-03 | Igm Biosciences, Inc. | IgA multi-specific binding molecules |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
SI3126383T1 (sl) | 2014-04-03 | 2019-05-31 | Igm Biosciences, Inc. | Modificirana veriga J |
SI3247728T1 (sl) | 2015-01-20 | 2020-09-30 | Igm Biosciences, Inc. | Super-družina receptorjev, ki vežejo molekule TNF (dejavnik tumorske nekroze), in njihova uporaba |
PT3265575T (pt) | 2015-03-04 | 2021-06-16 | Igm Biosciences Inc | Molécula de ligação a cd20 e seus usos |
EP3268392A2 (en) | 2015-03-13 | 2018-01-17 | CytomX Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
CN107921285B (zh) | 2015-03-25 | 2022-06-07 | Igm生物科学股份有限公司 | 多价乙型肝炎病毒抗原结合分子及其应用 |
CA2983034A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
EP3824903A1 (en) | 2015-09-30 | 2021-05-26 | IGM Biosciences Inc. | Binding molecules with modified j-chain |
CN108463472A (zh) | 2015-09-30 | 2018-08-28 | Igm生物科学有限公司 | 具有修饰的j-链的结合分子 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
JP7011764B2 (ja) | 2016-07-07 | 2022-01-27 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗体アジュバント複合体 |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
WO2018187702A2 (en) | 2017-04-07 | 2018-10-11 | Igm Biosciences A/S | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
EP3610022A1 (en) | 2017-04-14 | 2020-02-19 | Tollnine, Inc. | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
AU2018278327B2 (en) | 2017-06-01 | 2023-03-16 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies and methods of use thereof |
JP7410024B2 (ja) | 2017-11-17 | 2024-01-09 | ナンジン レジェンド バイオテク カンパニー リミテッド | Pd-l1に対する単一ドメイン抗体とその多様体 |
WO2019109974A1 (zh) * | 2017-12-06 | 2019-06-13 | 正大天晴药业集团南京顺欣制药有限公司 | 抗pd-l1抗体及其抗原结合片段 |
CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
KR20200108306A (ko) * | 2018-01-10 | 2020-09-17 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Pd-l1 항체 또는 이의 항원-결합 단편, 및 이의 약학적 용도 |
US11078283B2 (en) * | 2018-01-17 | 2021-08-03 | Apexigen, Inc. | Anti-PD-L1 antibodies and methods of use |
BR112020017296A2 (pt) | 2018-03-01 | 2020-12-29 | Igm Biosciences, Inc. | Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm |
TWI756621B (zh) * | 2019-01-25 | 2022-03-01 | 大陸商信達生物製藥(蘇州)有限公司 | 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體 |
KR20210132664A (ko) * | 2019-02-21 | 2021-11-04 | 유큐(베이징) 바이오파마 코., 엘티디 | 항pd-l1 항체 및 그의 용도 |
KR20220004634A (ko) | 2019-03-15 | 2022-01-11 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | Her2를 표적으로 하는 면역접합체 |
EP4013792A4 (en) * | 2019-08-15 | 2023-10-04 | IGM Biosciences Inc. | IMMUNO-STIMULATING MULTIMER BINDING MOLECULES |
CN110746493A (zh) * | 2019-09-06 | 2020-02-04 | 中国药科大学 | 一种pd-l1拮抗剂多肽及其应用 |
CN113121686A (zh) * | 2019-12-31 | 2021-07-16 | 迈威(上海)生物科技股份有限公司 | 抗pd-l1抗体及其应用 |
AU2021226023A1 (en) | 2020-02-28 | 2022-09-15 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
JP2023522962A (ja) | 2020-04-22 | 2023-06-01 | アイジーエム バイオサイエンシズ インコーポレイテッド | Pd-1アゴニスト多量体結合分子 |
CN113754775A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业(上海)股份有限公司 | 一种抗pd-l1和her2的双特异性抗体 |
JP2023531200A (ja) | 2020-06-18 | 2023-07-21 | ジェネンテック, インコーポレイテッド | 抗tigit抗体及びpd-1軸結合アンタゴニストを用いた治療 |
WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法 |
CN113943371B (zh) * | 2021-11-01 | 2023-05-05 | 达石药业(广东)有限公司 | 一种抗her2/抗pd-l1双功能抗体及其应用 |
WO2023178253A2 (en) * | 2022-03-18 | 2023-09-21 | Igm Biosciences, Inc. | Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
WO2006052641A2 (en) | 2004-11-05 | 2006-05-18 | Palingen, Inc. | Antibody induced cell membrane wounding |
CN114835812A (zh) * | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
CN103987405B (zh) * | 2011-11-28 | 2017-03-29 | 默克专利股份公司 | 抗pd‑l1抗体及其用途 |
EP2812356B1 (en) | 2012-02-08 | 2019-03-27 | IGM Biosciences, Inc. | Cdim binding proteins and uses thereof |
AU2014332458B2 (en) | 2013-09-05 | 2020-03-12 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies |
TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
US10822399B2 (en) | 2014-02-10 | 2020-11-03 | Igm Biosciences, Inc. | IgA multi-specific binding molecules |
SI3126383T1 (sl) | 2014-04-03 | 2019-05-31 | Igm Biosciences, Inc. | Modificirana veriga J |
JP6666905B2 (ja) * | 2014-05-29 | 2020-03-18 | スプリング バイオサイエンス コーポレーション | Pd−l1抗体及びその使用 |
US10544225B2 (en) * | 2014-07-03 | 2020-01-28 | Beigene, Ltd. | Anti-PD-L1 antibodies and their use as therapeutics and diagnostics |
CN107001463B (zh) * | 2014-08-05 | 2020-01-17 | 中美冠科生物技术(太仓)有限公司 | 抗pd-l1抗体 |
SI3247728T1 (sl) | 2015-01-20 | 2020-09-30 | Igm Biosciences, Inc. | Super-družina receptorjev, ki vežejo molekule TNF (dejavnik tumorske nekroze), in njihova uporaba |
PT3265575T (pt) | 2015-03-04 | 2021-06-16 | Igm Biosciences Inc | Molécula de ligação a cd20 e seus usos |
CN107921285B (zh) | 2015-03-25 | 2022-06-07 | Igm生物科学股份有限公司 | 多价乙型肝炎病毒抗原结合分子及其应用 |
CA2983034A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
CN108463472A (zh) * | 2015-09-30 | 2018-08-28 | Igm生物科学有限公司 | 具有修饰的j-链的结合分子 |
EP3824903A1 (en) | 2015-09-30 | 2021-05-26 | IGM Biosciences Inc. | Binding molecules with modified j-chain |
US20190330374A1 (en) | 2016-07-20 | 2019-10-31 | Igm Biosciences, Inc. | Multimeric ox40 binding molecules and uses thereof |
AU2017299610B2 (en) | 2016-07-20 | 2022-09-29 | Igm Biosciences, Inc. | Multimeric CD40 binding molecules and uses thereof |
EP3487299A4 (en) | 2016-07-20 | 2020-03-11 | IGM Biosciences, Inc. | MULTIMERICAL GITR FIXING MOLECULES |
AU2017299608A1 (en) | 2016-07-20 | 2019-02-07 | Igm Biosciences, Inc. | Multimeric CD137/4-1BB binding molecules and uses thereof |
WO2018187702A2 (en) | 2017-04-07 | 2018-10-11 | Igm Biosciences A/S | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
JP7358365B2 (ja) | 2018-02-26 | 2023-10-10 | アイジーエム バイオサイエンシズ インコーポレイテッド | がんを治療するための、化学療法剤と併用した多量体抗dr5結合分子の使用 |
BR112020017296A2 (pt) | 2018-03-01 | 2020-12-29 | Igm Biosciences, Inc. | Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm |
WO2020086745A1 (en) | 2018-10-23 | 2020-04-30 | Igm Biosciences, Inc. | MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES |
WO2020163646A1 (en) | 2019-02-08 | 2020-08-13 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
-
2017
- 2017-05-09 PT PT177242633T patent/PT3455257T/pt unknown
- 2017-05-09 HU HUE17724263A patent/HUE055972T2/hu unknown
- 2017-05-09 PL PL17724263T patent/PL3455257T3/pl unknown
- 2017-05-09 EP EP17724263.3A patent/EP3455257B1/en active Active
- 2017-05-09 KR KR1020187035104A patent/KR102343742B1/ko active IP Right Grant
- 2017-05-09 IL IL262295A patent/IL262295B2/en unknown
- 2017-05-09 AU AU2017264683A patent/AU2017264683B2/en active Active
- 2017-05-09 SG SG11201809336QA patent/SG11201809336QA/en unknown
- 2017-05-09 JP JP2018558733A patent/JP6979971B2/ja active Active
- 2017-05-09 WO PCT/US2017/031791 patent/WO2017196867A1/en unknown
- 2017-05-09 CA CA3021669A patent/CA3021669A1/en active Pending
- 2017-05-09 DK DK17724263.3T patent/DK3455257T3/da active
- 2017-05-09 US US16/098,479 patent/US10954302B2/en active Active
- 2017-05-09 CN CN201780027997.1A patent/CN109311985B/zh active Active
- 2017-05-09 ES ES17724263T patent/ES2899361T3/es active Active
-
2021
- 2021-02-10 US US17/172,790 patent/US20210163600A1/en not_active Abandoned
-
2023
- 2023-09-07 US US18/463,194 patent/US20240002514A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210163600A1 (en) | 2021-06-03 |
CN109311985B (zh) | 2022-09-30 |
PL3455257T3 (pl) | 2022-01-17 |
KR102343742B1 (ko) | 2021-12-24 |
US20240002514A1 (en) | 2024-01-04 |
CA3021669A1 (en) | 2017-11-16 |
EP3455257B1 (en) | 2021-09-22 |
AU2017264683A1 (en) | 2018-11-01 |
CN109311985A (zh) | 2019-02-05 |
HUE055972T2 (hu) | 2022-01-28 |
IL262295B2 (en) | 2023-09-01 |
KR20190003989A (ko) | 2019-01-10 |
AU2017264683B2 (en) | 2024-02-29 |
US20190338031A1 (en) | 2019-11-07 |
DK3455257T3 (da) | 2021-11-01 |
WO2017196867A1 (en) | 2017-11-16 |
EP3455257A1 (en) | 2019-03-20 |
JP2019519492A (ja) | 2019-07-11 |
IL262295A (en) | 2018-12-31 |
SG11201809336QA (en) | 2018-11-29 |
ES2899361T3 (es) | 2022-03-11 |
JP6979971B2 (ja) | 2021-12-15 |
IL262295B1 (en) | 2023-05-01 |
US10954302B2 (en) | 2021-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201900353B (en) | Anti-pd-l1 antibodies | |
IL262295A (en) | Antibodies against pd-l1 | |
HK1257164A1 (zh) | 新型抗pd-l1抗體 | |
HK1246324A1 (zh) | 抗pd-l1抗體 | |
IL255727A (en) | Novel anti-pd-l1 antibodies | |
LT3512547T (lt) | Antikūnai prieš pd-1 | |
IL264159A (en) | Anti-tim-3 antibodies | |
IL250415A0 (en) | Antibodies against pd-l1 | |
SG10201603721TA (en) | Anti-CTLA-4 Antibodies | |
GB201601073D0 (en) | Antibodies | |
GB201621439D0 (en) | IL-11Ra Antibodies | |
ZA201901865B (en) | Anti-pd-1 antibodies | |
GB201610044D0 (en) | Antibodies | |
IL262776A (en) | Human anti-il-1r3 antibodies | |
GB201603291D0 (en) | Antibodies | |
IL264262A (en) | Antibodies against interleukin 22 receptors | |
GB201616699D0 (en) | Antibodies | |
IL263406A (en) | Anti-tnfrs25 antibodies | |
GB201622197D0 (en) | Antibodies | |
GB201620414D0 (en) | Antibodies | |
GB201615224D0 (en) | Antibodies | |
GB201613158D0 (en) | Antibodies | |
GB201612437D0 (en) | Anti-lag-3 antibodies |